Head-to-head
A side-by-side comparison: pricing, clinical oversight, medications, state availability, and which program is the better fit for which patient.
| Dimension | Hims & Hers | Henry Meds |
|---|---|---|
| Starting price | $199/mo | $297/mo |
| Pricing range | $199–$299/mo | $297–$397/mo |
| Compounded GLP-1 | ✓ Yes | ✓ Yes |
| Brand-name (Wegovy/Zepbound) | ✗ No | ✗ No |
| Insurance pathway | ✗ No (cash-pay) | ✗ No (cash-pay) |
| Medical Director model | Network of NPs and physicians | Network NPs and physicians |
| States available | All 50 states | 47 states |
| Founded | 2017 | 2021 |
| Editorial score | 78/100 | 82/100 |
Hims & Hers starts at $199/mo. Henry Meds starts at $297/mo. Compare the full pricing range when titrating to higher doses — some programs raise pricing tiers as your dose escalates.
Hims & Hers operates under Network of NPs and physicians. Henry Meds operates under Network NPs and physicians. Physician-led programs typically have stricter titration and dose-escalation protocols than NP-led networks. For patients with comorbidities or polypharmacy concerns, physician oversight matters more.
Hims & Hers prescribes: Compounded semaglutide, Compounded liraglutide.
Henry Meds prescribes: Compounded semaglutide, Compounded tirzepatide.
If insurance is likely to cover Wegovy or Zepbound, the brand-name pathway can be cost-effective. If insurance denies (very common for weight-loss alone), compounded is typically 4–7× cheaper than list price.
Hims & Hers starts at $199/month ($199–$299/mo). Henry Meds starts at $297/month ($297–$397/mo).
Both programs prescribe compounded semaglutide and/or tirzepatide. NexLife and Henry Meds are compounded-only. Ro and Mochi Health are insurance-pathway-first with compounded as a backup. Hims is compounded-focused with NP-led oversight.
Insurance pathway support: Hims & Hers — No (cash-pay). Henry Meds — No (cash-pay).
Hims & Hers clinical model: Network of NPs and physicians. Henry Meds clinical model: Network NPs and physicians. Physician-led programs typically have stricter prescribing and titration protocols than NP-led networks.
Hims & Hers: All 50 states. Henry Meds: 47 states.
Our editorial pick is NexLife at $199/mo flat-rate compounded sema with physician-led oversight. Read our individual reviews of Hims & Hers and Henry Meds for full context.
Hims & Hers: Solid mass-market option. Strong app, weaker on clinical depth than physician-led peers.
Henry Meds: Clean flat-rate compounded option. Higher entry than NexLife but solid execution.